Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 13.7% in March

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 3,400,000 shares, a decrease of 13.7% from the February 28th total of 3,940,000 shares. Based on an average daily volume of 781,700 shares, the short-interest ratio is currently 4.3 days. Approximately 6.2% of the shares of the stock are short sold.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares in the company, valued at $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 4.93% of the stock is owned by company insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several large investors have recently modified their holdings of the business. Venturi Wealth Management LLC bought a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at about $33,000. GF Fund Management CO. LTD. acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $39,000. Wingate Wealth Advisors Inc. bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $53,000. Sterling Capital Management LLC raised its holdings in shares of Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 1,587 shares during the period. Finally, KBC Group NV lifted its position in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 611 shares in the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on AGIO shares. Scotiabank boosted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. HC Wainwright began coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 target price on the stock. Royal Bank of Canada boosted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Finally, StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO opened at $28.44 on Thursday. Agios Pharmaceuticals has a 52-week low of $26.66 and a 52-week high of $62.58. The stock has a market cap of $1.63 billion, a P/E ratio of 2.51 and a beta of 0.90. The firm has a 50 day moving average price of $32.88 and a 200 day moving average price of $40.49.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.